U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system

Symplicity blood pressure procedure is now covered for qualifying Medicare patients

GALWAY, Ireland, Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity blood pressure procedure. This final determination will now provide Medicare patients with access to the Symplicity blood pressure procedure for the treatment of uncontrolled hypertension, or high blood pressure. 

Read more at prnewswire.com